Compared to C-Kit−-LSECs, we secondly clarified that C-Kit+-LSECs had the abilities to reverse steatosis, inflammation and fibrosis of NASH; while upregulate prolipolytic FXR/PPAR-α, downregulate proinflammational TNF-α and profibtotic α-SMA in vitro and in vivo. Here, KIT is linked to metabolic dysfunction-associated steatohepatitis.